BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase

Rhea-AI Summary

BrightSpring Health Services (NASDAQ: BTSG) priced a previously announced underwritten secondary offering of 20,000,000 shares at $41.15 per share, expected to close on March 4, 2026. No shares are being sold by the company; selling stockholders will receive all proceeds.

The company authorized a concurrent repurchase of 1,464,807 shares from the underwriter at the offering price; the repurchase is conditioned on and expected to close simultaneously with the offering. Goldman Sachs is sole book-running manager and the offering relies on an S-3 shelf registration filed June 10, 2025.

Positive

• Concurrent repurchase of 1,464,807 shares authorized
• Underwriter will not receive fees on repurchased shares
• Offering priced at $41.15 for 20,000,000 shares

Negative

• Secondary sale of 20,000,000 shares increases public float
• BrightSpring will receive no proceeds from the offering
• Repurchase is conditioned on offering close and may not occur

Key Figures

Secondary shares: 20,000,000 shares Offering price: $41.15 per share Company repurchase size: 1,464,807 shares +5 more

8 metrics

Secondary shares 20,000,000 shares Selling stockholders’ underwritten secondary offering

Offering price $41.15 per share Public offering price for secondary shares

Company repurchase size 1,464,807 shares Shares to be repurchased concurrently from underwriter

Offering close date March 4, 2026 Expected closing date subject to conditions

Last close price $41.58 BTSG share price prior to news

52-week high $44.87 Pre-news 52-week high level

52-week low $15.48 Pre-news 52-week low level

Shares outstanding (pre) 193,549,161 shares Pre-offering share count per 424B7 filing

Market Reality Check

Price: $41.43 Vol: Volume 2,885,312 is 1.56x...

high vol

$41.43 Last Close

Volume Volume 2,885,312 is 1.56x the 20-day average of 1,848,717, indicating elevated trading interest into the secondary and buyback. high

Technical Shares trade above the $29.77 200-day MA, about 7.33% below the $44.87 52-week high and well above the $15.48 52-week low.

Peers on Argus

BTSG was modestly higher (+0.36%) while momentum scanners flagged only DOCS movi...

1 Down

BTSG was modestly higher (+0.36%) while momentum scanners flagged only DOCS moving down (-3.74%) in the broader peer group, suggesting today’s setup is stock-specific rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 27	Earnings results	Positive	+3.2%	Strong FY2025 results and 2026 guidance with revenue and EBITDA growth.
Feb 17	Investor Day announcement	Positive	+7.0%	Announcement of detailed Investor Day with leadership presentations and Q&A.
Feb 03	Earnings date notice	Neutral	-4.5%	Scheduling notice for Q4 and full-year 2025 results release and call.
Oct 28	Earnings results	Positive	+0.1%	Q3 2025 beat with raised full-year revenue guidance and higher EBITDA.
Oct 20	Secondary & buyback	Positive	+5.8%	Secondary sale by holders with concurrent company repurchase of 1.5M shares.

Pattern Detected

Recent BTSG news has usually seen positive alignment between constructive announcements (earnings, capital actions, Investor Day) and subsequent price gains, with only one notable divergence on an earnings date notice.

Recent Company History

Over the last several months, BTSG has reported strong results and active capital actions. Q3 2025 earnings on Oct 28, 2025 featured double-digit growth and a modestly positive reaction. A prior secondary plus concurrent buyback on Oct 20, 2025 saw a 5.84% gain, indicating markets previously viewed this structure constructively. Strong FY2025 results and 2026 guidance on Feb 27, 2026 were followed by a 3.24% rise, and the upcoming Mar 17, 2026 Investor Day also drew a strong positive response.

Market Pulse Summary

This announcement combines a 20,000,000-share secondary sale by existing holders at $41.15 with a co...

Analysis

This announcement combines a 20,000,000-share secondary sale by existing holders at $41.15 with a concurrent company repurchase of 1,464,807 shares from the underwriter. No new shares are issued and the company receives no offering proceeds. Historically, a similar October 2025 structure coincided with a 5.84% gain, so investors may compare terms, seller mix, and execution of the repurchase when evaluating future updates.

Key Terms

secondary offering, share repurchase, underwriter, book-running manager, +3 more

7 terms

secondary offering financial

"pricing of the previously announced underwritten secondary offering by certain of its stockholders"

A secondary offering is when a company sells new shares of its stock to the public after its initial sale. This allows existing shareholders or the company itself to raise additional money. For investors, it can impact the stock’s price by increasing the total number of shares available, which may influence the stock’s value and how the market perceives the company’s financial health.

share repurchase financial

"concurrent purchase from the underwriter, out of the 20,000,000 shares of common stock being sold"

A share repurchase is when a company uses cash to buy its own shares from the market, reducing the number of shares available to outside investors. Like a homeowner buying back rooms in a shared house to increase their own stake, repurchases can raise earnings per share and often signal management thinks the stock is undervalued, but they also use up cash that could have gone to dividends, investments, or debt reduction — all important considerations for investors.

underwriter financial

"purchase from the underwriter, out of the 20,000,000 shares of common stock"

An underwriter is a financial firm that evaluates, guarantees and helps sell a new security offering—such as a stock or bond—by buying the issue from the issuer and reselling it to investors or organizing the sale. Think of them as a bridge or safety net: they take on the risk, set the price, handle marketing and paperwork, and their work determines how much money a company can raise and how smoothly the offering reaches the market.

book-running manager financial

"Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering"

A book-running manager is the lead organizer responsible for coordinating a large financial sale, such as issuing new stocks or bonds. They oversee preparing all necessary documents, setting the sale’s price, and finding buyers, much like a concert promoter arranging a major event. Their role matters to investors because they help ensure the offering is successfully sold at the best possible terms.

prospectus regulatory

"A shelf registration statement (including a prospectus) on Form S-3 relating to these securities"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

preliminary prospectus supplement regulatory

"The offering of these securities will be made only by means of a preliminary prospectus supplement"

A preliminary prospectus supplement is an initial document that provides important details about a new stock or bond offering before it is finalized. It helps investors understand what is being sold and why, so they can decide whether to invest. Think of it as a preview before the full sales brochure is ready.

public offering financial

"any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

AI-generated analysis. Not financial advice.

LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced the pricing of the previously announced underwritten secondary offering by certain of its stockholders (the “Selling Stockholders”), including an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management, of an aggregate 20,000,000 shares of common stock of BrightSpring, at the public offering price of $41.15 per share. No shares are being sold by BrightSpring in the offering. The Selling Stockholders will receive all of the proceeds from this offering. The offering is expected to close on March 4, 2026, subject to customary closing conditions.

In addition, the Company has authorized, subject to the completion of the offering, the concurrent purchase from the underwriter, out of the 20,000,000 shares of common stock being sold as part of the secondary public offering, 1,464,807 shares of common stock at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the offering. The offering is not conditioned upon the completion of the share repurchase.

Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering.

A shelf registration statement (including a prospectus) on Form S-3 relating to these securities was filed with the Securities and Exchange Commission on June 10, 2025 and became automatically effective upon filing. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus for the offering may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.

Forward Looking Statements

The statements contained in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on BrightSpring’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These expectations, beliefs, and projections are expressed in good faith and BrightSpring believes there is a reasonable basis for them. However, there can be no assurance that these expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond BrightSpring’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in BrightSpring’s filings with the SEC under caption “Risk Factors,” including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent other filings BrightSpring makes with the SEC from time to time. Any forward-looking statement in this press release speaks only as of the date of this release. BrightSpring undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com

or

Media Contact:
Leigh White
leigh.white@brightspringhealth.com
502.630.7412

FAQ

What did BrightSpring (BTSG) announce about the March 2026 secondary offering?

BrightSpring priced a 20,000,000-share secondary offering at $41.15 per share, expected to close March 4, 2026. According to the company, no shares were sold by BrightSpring and selling stockholders will receive all proceeds; Goldman Sachs is sole book-running manager and S-3 coverage applies.

Will BrightSpring (BTSG) receive proceeds from the 20,000,000-share offering?

No, BrightSpring will not receive proceeds; the selling stockholders will receive all proceeds from the offering. According to the company, the offering sells shares held by existing holders, is expected to close March 4, 2026, and the company authorized a concurrent repurchase.

What are the terms of BrightSpring's (BTSG) concurrent share repurchase?

BrightSpring authorized purchase of 1,464,807 shares from the underwriter at the offering price, simultaneous with the offering close. According to the company, the repurchase is conditioned on the offering closing and the underwriter will not receive fees on repurchased shares, per the announcement.

When will the BrightSpring (BTSG) offering close and what filings support it?

The offering is expected to close on March 4, 2026, subject to customary closing conditions. According to the company, the securities are covered by an S-3 shelf registration filed June 10, 2025 and a prospectus supplement will be used for the offering.